Apotex Health Corp. Raises $1.5B in Upsized IPO, SK Capital Cuts Stake
Event summary
- Apotex Health Corp. closed an upsized IPO on June 16, 2026, raising $1.5B through 62.3M common shares at $24 each.
- The offering included a $850M treasury offering and a $645M secondary offering, with the over-allotment option fully exercised.
- SK Capital Partners reduced its stake from 75.3% to 52.4% post-IPO, selling 25.7M shares for approximately $616M.
- Sherfam's stake decreased from 16.8% to 14.2% post-IPO, maintaining its position as a significant shareholder.
The big picture
Apotex's $1.5B IPO marks a significant milestone in the pharmaceutical sector, providing capital for expansion while reshaping ownership dynamics. SK Capital Partners' partial exit signals a shift in governance, potentially influencing Apotex's strategic agility in a market increasingly focused on affordable and innovative healthcare solutions.
What we're watching
- Investor Commitment
- How SK Capital Partners' reduced stake will impact Apotex's strategic direction and market perception.
- Market Performance
- Whether Apotex can sustain momentum post-IPO amid competitive pharmaceutical market dynamics.
- Execution Risk
- The pace at which Apotex integrates proceeds to drive growth in its global health portfolio.
Related topics